BETWEEN PROTALIX LTD. as the Company AND ALTSHULER SHAHAM TRUSTS LTD. as Security TrusteeSecurity Agreement • August 26th, 2021 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • Tel-Aviv
(A)On December 7, 2016, an indenture was entered into among Protalix Biotherapeutics, Inc., a Delaware corporation, as Issuer (the “Issuer”), the Guarantors party thereto, and the Bank of New York Mellon Trust Company, N.A., as Trustee on behalf of certain holders (the “Trustee”), and Wilmington Savings Fund Society, FSB, as Collateral Agent, pursuant to which the Issuer issued notes to certain holders on the terms set forth therein, as amended from time to time (the “Existing Indenture”).
PROTALIX BIOTHERAPEUTICS, INC. AS ISSUER AND EACH OF THE GUARANTORS PARTY HERETO 7.50% SENIOR SECURED CONVERTIBLE NOTES DUE 2024 INDENTURE DATED AS OF AUGUST 24, 2021 THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A. AS TRUSTEE WILMINGTON SAVINGS FUND...Protalix BioTherapeutics, Inc. • August 26th, 2021 • Biological products, (no disgnostic substances) • New York
INDENTURE, dated as of August 24, 2021, among Protalix Biotherapeutics, Inc., a Delaware corporation (“Company”), the Guarantors (as defined below) party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), registrar, paying agent and conversion agent, and Wilmington Savings Fund Society, FSB (“WSFS”), as the collateral agent (the “Collateral Agent”).
AMENDED AND RESTATED SECURITY AGREEMENT dated as of August 24, 2021 among PROTALIX BIOTHERAPEUTICS, INC., as Issuer THE GUARANTORS PARTY HERETO, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Collateral AgentSecurity Agreement • August 26th, 2021 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This AMENDED AND RESTATED SECURITY AGREEMENT dated as of August 24, 2021 (the “Effective Date”), among Protalix BioTherapeutics, Inc., as issuer (the “Issuer”), the Guarantors (as defined below) party hereto, Wilmington Savings Fund Society, FSB, as the collateral agent (in such capacity, together with its successors and permitted assigns in such capacity, the “Collateral Agent”), and The Bank of New York Mellon Trust Company, N.A., as Trustee under the 2021 Notes Indenture (as defined below) (in such capacity, together with its successors and permitted assigns in such capacity, the “2021 Notes Trustee”) and as Trustee under the 2024 Notes Indenture (as defined below) (in such capacity, together with its successors and permitted assigns in such capacity, the “2024 Notes Trustee”, and the 2024 Notes Trustee, together with the 2021 Notes Trustee, the “Trustee”).
THIRD Supplemental Indenture by and among PROTALIX BIOTHERAPEUTICS, INC., as Issuer, AND EACH OF THE GUARANTORS PARTY HERETO, and The Bank of New York Mellon Trust CoMPANY, N.A., as Trustee, and wilmington savings fund society, fsb, as Collateral AgentThird Supplemental Indenture • August 26th, 2021 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances)
THIRD SUPPLEMENTAL INDENTURE, dated as of August 24, 2021 (this “Third Supplemental Indenture”), by and among PROTALIX BIOTHERAPEUTICS, INC., a Delaware corporation (the “Company”), as issuer, the guarantors party hereto (the “Guarantors”), The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), Registrar, Paying Agent and Conversion Agent, and Wilmington Savings Fund Society, FSB, as the collateral agent (the “Collateral Agent”), under an Indenture, dated as of December 7, 2016, by and among the Company, each of the Guarantors party thereto, the Collateral Agent, and the Trustee (the “Base Indenture”), as supplemented by the First Supplemental Indenture, dated July 24, 2017 (the “First Supplemental Indenture”) and the Second Supplemental Indenture, dated November 27, 2017 (the “Second Supplemental Indenture”). All capitalized terms used in this Third Supplemental Indenture and not otherwise defined herein have the meanings given to such terms in the Base Indenture
